Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02 olomorasib combinations in resected or unresectable KRAS G12C-mutant non-small cell lung cancer
NL-OMON61092Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Disease-free survival and Progression-free survival. Started May 2025; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61092.